Acute pancreatitis laboratory findings

Acute pancreatitis Microchapters
Home
American College of Gastroenterology Guidelines
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Acute Pancreatitis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic criteria
History and Symptoms
Physical Examination
Laboratory Findings
Abdominal X Ray
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Approach to Therapy
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Acute pancreatitis laboratory findings On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Acute pancreatitis laboratory findings All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Acute pancreatitis laboratory findings
CDC on Acute pancreatitis laboratory findings
Acute pancreatitis laboratory findings in the news
Blogs on Acute pancreatitis laboratory findings
Directions to Hospitals Treating Acute pancreatitis
Risk calculators and risk factors for Acute pancreatitis laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Monish Thuvooru Muthu Kalyanaraman, M.B.B.S[2]

Laboratory Findings

Laboratory testing in acute pancreatitis serves three distinct purposes: (1) confirming the diagnosis (lipase or amylase ≥3× ULN as one of the revised Atlanta criteria), (2) identifying the underlying etiology (liver enzymes for biliary cause, triglycerides, calcium, IgG4), and (3) assessing severity and guiding management (BUN, hematocrit, CRP, procalcitonin). Once the diagnosis is established, serial trending of amylase or lipase is not recommended because enzyme levels do not correlate with severity, prognosis, or readiness for refeeding or discharge.

Diagnostic Enzymes: Lipase and Amylase

Serum Lipase (Preferred)

Serum lipase is the preferred diagnostic enzyme per the ACG 2024, IAP/APA 2013, and AGA 2018 guidelines.

• Rises within 4–8 hours of symptom onset and remains elevated for 8–14 days, providing a wider diagnostic window than amylase.
• At the ≥3× ULN threshold: sensitivity approximately 80% and specificity approximately 93% (Cochrane 2017 meta-analysis).
• Lipase is more sensitive than amylase and remains elevated longer, making it particularly useful in patients who present late after symptom onset.
• Lipase may be falsely elevated in nonpancreatic conditions — see the differential diagnosis microchapter for a full list of causes of nonpancreatic hyperlipasemia.

Serum Amylase

• Rises within a few hours of symptom onset but returns to normal within 3–5 days.
• At the ≥3× ULN threshold: sensitivity approximately 71% and specificity approximately 99% (Cochrane 2017).
• May be normal on admission in as many as one-fifth of patients with acute pancreatitis.
• False-negative results occur in alcohol-induced acute pancreatitis, hypertriglyceridemia-induced acute pancreatitis (interference with assay), and acute-on-chronic pancreatitis (depleted acinar cell mass).
• False-positive elevations occur with macroamylasemia, salivary gland disease (parotitis), decreased GFR, and extrapancreatic abdominal inflammation (appendicitis, cholecystitis, bowel obstruction or ischemia, peptic ulcer disease, gynecological conditions).

Lipase vs. Amylase: Key Points

• When only one test is ordered, lipase is preferred (ACG 2024: strong recommendation).
• Ordering both tests simultaneously adds minimal diagnostic value and is generally unnecessary.
• Neither amylase nor lipase levels correlate with disease severity — do not use the magnitude of elevation to predict outcomes.
• Once the diagnosis is established, there is no reason to follow serial lipase or amylase levels.

Etiologic Laboratory Workup

The following tests should be obtained at presentation to determine the etiology of acute pancreatitis:

• Liver panel (ALT, AST, alkaline phosphatase, total and direct bilirubin) — An ALT >3× ULN in the setting of acute pancreatitis has a positive predictive value of 95% for a biliary etiology. However, 15–20% of patients with gallstone pancreatitis present with normal liver enzymes, so a biliary cause cannot be excluded by normal LFTs alone.
• Serum triglycerides — Should be obtained on admission. Levels ≥1,000 mg/dL (11.3 mmol/L) are considered causative. Triglyceride levels may fall rapidly during fasting, so early measurement is essential. Hypertriglyceridemia may also interfere with amylase assays, producing falsely normal results.
• Serum calcium — Hypercalcemia is a rare but treatable cause of acute pancreatitis. Calcium should be measured at admission as part of the etiologic workup.
• IgG4 — Should be obtained when autoimmune pancreatitis is suspected (e.g., diffuse pancreatic enlargement on imaging, lack of typical risk factors). Elevation is suggestive but not pathognomonic for autoimmune pancreatitis.

Severity and Prognostic Markers

No single laboratory test reliably predicts severity; clinical assessment and composite scoring systems are preferred. However, several individual markers have prognostic value:

• Blood urea nitrogen (BUN) — Elevated BUN (≥20 mg/dL) and rising BUN within the first 24 hours reflect intravascular volume depletion and are associated with increased morbidity and mortality. BUN can also be used to monitor the response to fluid resuscitation.
• Hematocrit — Elevated hematocrit (≥44%) reflects hemoconcentration from third-space losses and is an early marker of severe disease. A rising hematocrit at 24 hours is a reliable predictor of persisting organ failure and mortality.
• Serum creatinine — Elevated creatinine (>1.8 mg/dL [159 μmol/L]) is associated with moderately severe and severe acute pancreatitis and corresponds to a renal score of ≥2 on the modified Marshall scoring system, defining renal organ failure.
• C-reactive protein (CRP) — CRP >150 mg/L at 48 hours is a well-validated marker of necrotizing pancreatitis and severe disease. Its major limitation is that it takes 48–72 hours to become accurate, by which time clinical trajectory is usually apparent.
• Procalcitonin (PCT) — Persistently elevated PCT is an indicator of disease severity, necrosis, and infected pancreatic necrosis. PCT >1.8 ng/mL on at least two consecutive days predicts infected necrosis with sensitivity 94% and specificity 91%. PCT >1 ng/mL in the setting of raised inflammatory markers but without positive cultures can serve as an indicator for initiating antibiotic therapy (expert recommendation).

Routine Laboratory Panel at Admission

Based on current guidelines (ACG 2024, IAP/APA 2013), the following panel should be obtained at presentation in all patients with suspected acute pancreatitis:

• Serum lipase (preferred) or amylase
• Complete blood count with differential
• Basic metabolic panel (BUN, creatinine, glucose, calcium, electrolytes)
• Liver panel (ALT, AST, alkaline phosphatase, bilirubin)
• Serum triglycerides
• Lactate (if hemodynamically unstable or mesenteric ischemia suspected)

Additional tests as indicated:

• CRP (most useful at 48 hours for predicting necrosis)
• Procalcitonin (if concern for infected necrosis or need for antibiotic decision)
• IgG4 (if autoimmune pancreatitis suspected)
• Arterial blood gas (if respiratory distress or severe disease)
• Pregnancy test (women of reproductive age)

Monitoring Laboratory Tests During Hospitalization

• BUN and creatinine — Serial measurement during the first 24–48 hours to assess fluid resuscitation adequacy. Falling BUN indicates adequate volume repletion.
• Hematocrit — Trending during the first 24 hours to assess hemoconcentration.
• CRP — Most informative at 48 hours; CRP >150 mg/L should prompt consideration of cross-sectional imaging to evaluate for necrosis.
• Serum calcium — Declining calcium is a marker of severity (Ranson criterion); may also cause symptoms (tetany, QT prolongation).
• Blood glucose — Hyperglycemia is common and may reflect pancreatic endocrine insufficiency in necrotizing pancreatitis.

Clinically Actionable Recommendations

• Order serum lipase (not amylase) as the primary diagnostic enzyme. There is no need to order both routinely.
• Obtain a liver panel, triglycerides, and calcium at admission to identify etiology.
• Do not follow serial lipase or amylase after diagnosis — they have no prognostic value and do not guide decisions about refeeding or discharge.
• Use BUN and hematocrit trends in the first 24 hours as early bedside markers of severity and adequacy of fluid resuscitation.
• Obtain CRP at 48 hours to assess for necrotizing pancreatitis; CRP >150 mg/L warrants imaging evaluation.
• Consider procalcitonin when infected necrosis is suspected; PCT >1 ng/mL with raised inflammatory markers can guide antibiotic initiation in the absence of positive cultures.